Purdue student venture fund invests in Kylin Therapeutics

Purdue University’s Student-Managed Venture Fund is betting its bank on West Lafayette-based biotech startup Kylin Therapeutics

This month, MBA students in the Krannert Graduate School of Management invested $100,000 in Kylin, which represents 77 percent
of their fund’s total assets. Kylin, in the Purdue Research Park, is in the preclinical stage of commercializing a technology
to target and "turn off" diseasecausing genes.

Including the student’s investment, Kylin last month raised $2 million in a venture capital round led by West Lafayette-based
In-vivo Ventures and Durham, N.C.-based Golden Pine Ventures. The company plans to use the money to advance its cancer therapy
to the marketplace.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.